Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Hedgehog signaling pathway | R-HSA-5358351 | map04340 | thiethylperazine | 5440 | drug-path |
| Long-term potentiation | R-HSA-9620244 | map04720 | thiethylperazine | 5440 | drug-path |
| GnRH signaling pathway | R-HSA-168638 | map04912 | thiethylperazine | 5440 | drug-path |
| Colorectal cancer | R-HSA-4791275 | map05210 | thiethylperazine | 5440 | drug-path |
| Vascular smooth muscle contraction | R-HSA-445355 | map04270 | thiethylperazine | 5440 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | diethylstilbestrol | 448537 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | diethylstilbestrol | 448537 | drug-path |
| MAPK signaling pathway | R-HSA-9652817 | map04010 | diethylstilbestrol | 448537 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | diethylstilbestrol | 448537 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | diethylstilbestrol | 448537 | drug-path |
| SNARE interactions in vesicular transport | R-HSA-428625 | map04130 | diethylstilbestrol | 448537 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | diethylstilbestrol | 448537 | drug-path |
| Shigellosis | 0 | map05131 | diethylstilbestrol | 448537 | drug-path |
| Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | diethylstilbestrol | 448537 | drug-path |
| Notch signaling pathway | R-HSA-157118 | map04330 | diethylstilbestrol | 448537 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | hyoscyamine | 8955 | drug-path |
| Focal adhesion | R-HSA-354113 | map04510 | hyoscyamine | 8955 | drug-path |
| Type II diabetes mellitus | R-HSA-2127377 | map04930 | hyoscyamine | 8955 | drug-path |
| Glioma | Q9NZM4 | map05214 | hyoscyamine | 8955 | drug-path |
| Phosphatidylinositol signaling system | R-HSA-1280215 | map04070 | hyoscyamine | 8955 | drug-path |